FBB
PHAT icon

Fulton Breakefield Broenniman’s Phathom Pharmaceuticals PHAT Stock Holding History

Fulton Breakefield Broenniman’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,579
Closed -$243K – 190
2024
Q2 		$243K Hold
23,579
– – 0.02% 165
2024
Q1 		$250K Hold
23,579
– – 0.02% 161
2023
Q4 		$215K Buy
+23,579
New +$203K 0.02% 168

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fulton Breakefield Broenniman's PHAT Position: Q3 2024 in Review

Fulton Breakefield Broenniman sold out of Phathom Pharmaceuticals (PHAT) in Q3 2024, closing a stake of 23,579 shares — an estimated $243K sold.

Fulton Breakefield Broenniman first reported a position in PHAT in Q4 2023 and held it in 3 quarters. The position peaked at $250K in Q1 2024. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2024.

  • Fulton Breakefield Broenniman reported no remaining Phathom Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Fulton Breakefield Broenniman sold 23,579 Phathom Pharmaceuticals shares in Q3 2024, an estimated $243K.
  • Fulton Breakefield Broenniman first reported a position in Phathom Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Fulton Breakefield Broenniman's Phathom Pharmaceuticals position peaked at $250K in Q1 2024.
  • 133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2024.

Based on Fulton Breakefield Broenniman's 13F filing for Q3 2024, filed 16 Oct 2024.